Carcinoembryonic antigen-based vaccines

Seminars in Oncology

Volumn 30, Issue 3 SUPPL. 8, 2003, Pages 30-36

  Marshall, John ^a,b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALVAC CEA VACCINE; B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A2 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; RECOMBINANT CARCINOEMBRYONIC ANTIGEN VACCINIA VIRUS VACCINE; TRICOM VACCINE; TUMOR MARKER; UNCLASSIFIED DRUG;

APPENDIX CANCER; BREAST CANCER; CANCER IMMUNOTHERAPY; CELL ADHESION; CLINICAL TRIAL; COLORECTAL CANCER; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; ESOPHAGUS CANCER; FOWLPOX VIRUS; GALLBLADDER CANCER; HUMAN; LUNG CANCER; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; THYROID CANCER; VACCINATION; VACCINIA VIRUS; VIRUS RECOMBINANT;

EID: 0042303769     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(03)00233-1     Document Type: Review

References (12)

1. Marshall JL, Hawkins MJ, Tsang KY, et al: Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J Clin Oncol 17:332-337, 1999
2. Benchimol S, Fuks A, Jothy S, et al: Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57:327-332, 1989
3. Kantor J, Irvine K, Abrams S, et al: Antitumor activity and immune responses induced by a recombinant carcinoembryonic antigen-vaccinia virus vaccine. J Natl Cancer Inst 84:1084-1091, 1992
4. Tsang KY, Zaremba S, Nieroda CA, et al: Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 87:982-990, 1995
5. Hodge JW, Schlom J: Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res 59:5106-5111, 1999
6. von Mehren M, Arlen P, Tsang KY, et al: Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res 6:2219-2228, 2000
7. Hodge JW, McLaughlin JP, Kantor JA: Diversified prime and boost protocols using recombinant vaccinia virus and recombinant nonreplicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 16:759-768, 1997
8. Marshall JL, Hoyer RJ, Toomey MA, et al: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinogenic antigen immune responses. J Clin Oncol 18:3964-3973, 2000
9. Marshall JL, Tsang K, Arlen P, et al: Phase I trial to determine the toxicity and immunologic efficacy of the addition of GM-CSF (GM) and IL-2 to the combination of vaccinia-CEA (V) and ALVAC-CEA (A) administered as a prime and boost in patients with advanced CEA-bearing cancers. Proc Am Soc Clin Oncol 20:272A, 2001 (abstr 1087)
10. Hodge JW, Sabzevari H, Yafal AG, et al: A triad of costimulatory molecules synergize to amplify T cell activation. Cancer Res 59:5800-5807, 1999
11. Aarts WM, Schlom J, Hodge JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self antigen and antitumour activity. Cancer Res 62:5770-5777, 2002
12. Marshall JL, Arlen PM, Rizvi N, et al: A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas. Proc Am Soc Clin Oncol 21:7A, 2002 (abstr 24)